The 5-fluorouracil (5-FU) metabolic pathway is mainly dependent on the activity of several intracellular enzymes. Among them, four in particular; thymidylate synthase, methylenetetrahydrofolate reductase, dihydropyrimidine dehydrogenase and thymidine phosphorylase are considered the key points in determining sensitivity or resistance to this drug. These enzymes are needed to metabolize the drug in its active form (thymidylate phosphorylase) or to drop the concentration of the active drug in the cell (dihydropyrimidine dehydrogenase) or both (thymidylate synthase and methylenetetrahydrofolate reductase). Several different studies have tried to investigate the relationship between the presence of mutations in these enzymes and a reduced/improved activity of treatment based on 5-FU or its derivatives. In this article, we will focus on the often contradictory results of these studies.

5-Fluorouracil pharmacogenomics: still rocking after all these years? / M., Scartozzi; E., Maccaroni; R., Giampieri; M., Pistelli; A., Bittoni; M. D., Prete; R., Berardi; Cascinu, Stefano. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 12:2(2011), pp. 251-265. [10.2217/pgs.10.167]

5-Fluorouracil pharmacogenomics: still rocking after all these years?

CASCINU, Stefano
2011

Abstract

The 5-fluorouracil (5-FU) metabolic pathway is mainly dependent on the activity of several intracellular enzymes. Among them, four in particular; thymidylate synthase, methylenetetrahydrofolate reductase, dihydropyrimidine dehydrogenase and thymidine phosphorylase are considered the key points in determining sensitivity or resistance to this drug. These enzymes are needed to metabolize the drug in its active form (thymidylate phosphorylase) or to drop the concentration of the active drug in the cell (dihydropyrimidine dehydrogenase) or both (thymidylate synthase and methylenetetrahydrofolate reductase). Several different studies have tried to investigate the relationship between the presence of mutations in these enzymes and a reduced/improved activity of treatment based on 5-FU or its derivatives. In this article, we will focus on the often contradictory results of these studies.
2011
12
2
251
265
5-Fluorouracil pharmacogenomics: still rocking after all these years? / M., Scartozzi; E., Maccaroni; R., Giampieri; M., Pistelli; A., Bittoni; M. D., Prete; R., Berardi; Cascinu, Stefano. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 12:2(2011), pp. 251-265. [10.2217/pgs.10.167]
M., Scartozzi; E., Maccaroni; R., Giampieri; M., Pistelli; A., Bittoni; M. D., Prete; R., Berardi; Cascinu, Stefano
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1079320
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 52
  • ???jsp.display-item.citation.isi??? 51
social impact